Agonist-specific cross talk between ERKs and p38mapk regulates PGI2 synthesis in endothelium

Rebecca A. Houliston1, Jeremy D. Pearson2, and Caroline P. D. Wheeler-Jones1

1 Department of Veterinary Basic Sciences, The Royal Veterinary College, University of London, London NW1 0TU; and 2 Centre for Cardiovascular Biology and Medicine, King's College London, London SE1 1UL, United Kingdom


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

We have examined the mechanisms regulating prostacyclin (PGI2) synthesis after acute exposure of human umbilical vein endothelial cells (HUVEC) to interleukin-1alpha (IL-1alpha ). IL-1alpha evoked an early (30 min) release of PGI2 and [3H]arachidonate that was blocked by the cytosolic phospholipase A2alpha (cPLA2alpha ) inhibitor arachidonyl trifluoromethyl ketone. IL-1alpha -mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2; p42/p44mapk) coincided temporally with phosphorylation of cPLA2alpha and with the onset of PGI2 synthesis. The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1alpha -induced ERK activation and partially attenuated cPLA2alpha phosphorylation and PGI2 release, suggesting that ERK-dependent and -independent pathways regulate cPLA2alpha phosphorylation. SB-203580 treatment enhanced IL-1alpha -induced MEK, p42/44mapk, and cPLA2alpha phosphorylation but reduced thrombin-stimulated MEK and p42/44mapk activation. IL-1alpha , but not thrombin, activated Raf-1 as assessed by immune-complex kinase assay, as did SB-203580 alone. These results show that IL-1alpha causes an acute upregulation of PGI2 generation in HUVEC, establish a role for the MEK/ERK/cPLA2alpha pathway in this early release, and provide evidence for an agonist-specific cross talk between p38mapk and p42/44mapk that may reflect receptor-specific differences in the signaling elements proximal to MAPK activation.

human endothelium; interleukin-1; thrombin; mitogen-activated protein kinases; cytosolic phospholipase A2alpha ; prostacyclin; extracellular signal-regulated kinase


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

PROSTACYCLIN (PGI2), a potent vasodilator and inhibitor of platelet aggregation, is synthesized by vascular endothelial cells (ECs) in response to a variety of stimuli. G protein-coupled receptor agonists (e.g., thrombin) generally elicit a very rapid, short-lived PGI2 release (8, 44, 46). In contrast, early studies in ECs revealed that PGI2 generation in response to proinflammatory cytokines only became apparent after continuous exposure to agonist for several hours (24, 31). Three key enzymatic steps are involved in PGI2 generation, all of which are potentially important regulatory sites. Phospholipase A2 (PLA2) enzymes catalyze the cleavage of arachidonic acid (AA) from the sn-2 position of phospholipids (e.g., Ref. 21) with subsequent conversion of free AA into prostaglandin (PG) H2 by two distinct isoforms of cyclooxygenase (COX; Ref. 15); newly formed PGH2 is then converted to PGI2 by terminal PGI2 synthase (26). The protracted PGI2 generation in response to interleukin-1 (IL-1) has been attributed to enhanced expression of COX-2, the inducible form of COX, and to increased cytosolic PLA2alpha (cPLA2alpha ) expression (11, 15, 24, 31). More recently it was suggested that IL-1 may elicit an acute prostanoid release from ECs (6), but the early signaling events responsible for this synthesis remain undefined.

The post-receptor signaling pathways regulating cytokine-driven prostanoid synthesis in vascular endothelium are poorly understood. However, the pleiotropic effects of IL-1 are known to result in part from the triggering of signaling cascades involving activation of families of serine/threonine protein kinases collectively known as the mitogen-activated protein kinases (MAPKs). MAPKs are activated by phosphorylation of specific threonine and tyrosine residues within the signature sequence Thr-X-Tyr catalyzed by upstream, dual-specificity MAPK kinases (MEKs) (reviewed in Ref. 41). Of the three major MAPK subgroups, the c-Jun NH2-terminal kinases (JNK/stress-activated protein kinases) and the p38 MAPKs (p38mapk) are thought to be important in mediating cellular responses to extracellular stress. Thus ultraviolet radiation, proinflammatory cytokines, and lipopolysaccharide strongly activate these MAPK families (37), and p38mapk has been implicated in the regulation of cytokine-stimulated E-selectin expression in endothelium (38). In contrast, the extracellular signal-regulated kinases (ERK1/2; also known as p42/p44mapk) are typically activated in response to mitogenic stimuli and are generally poorly stimulated by exposure to proinflammatory cytokines (reviewed in Ref. 25). We have recently shown that IL-1alpha and tumor necrosis factor-alpha (TNF-alpha ) transiently activate p42/p44mapk in human ECs (28). Because this activation does not appear to be obligatory for IL-1alpha -induced E-selection expression (45), and because its involvement in other IL-1alpha -mediated responses has yet to be explored, the functional significance of activation of the ERK pathway by proinflammatory cytokines in ECs is unclear.

The 85-kDa cPLA2alpha is one of a growing family of PLA2 enzymes (35, 40, 42) implicated in stimulus-evoked AA mobilization and is regulated by at least two major posttranslational mechanisms, both of which are thought to be essential for the initiation of AA release: 1) calcium-stimulated membrane association via its calcium-binding domain (39), and 2) phosphorylation of Ser505 within the sequence Pro-Leu-Ser-Pro typically recognized by proline-directed protein kinases, such as members of the MAPK families. p42mapk-mediated phosphorylation of Ser505 results in an increase in the specific activity of cPLA2alpha (13) and a characteristic shift in the electrophoretic mobility of the phosphorylated, active form of the enzyme (33). Evidence from studies carried out in platelets and neutrophils also implicates the p38mapk pathway in regulating the phosphorylation state of cPLA2alpha (14, 18, 43). Our recent studies have shown that p42mapk is likely to be an important regulator of PGI2 generation in thrombin- and vascular endothelial growth factor (VEGF)-stimulated human umbilical vein endothelial cells (HUVEC) via its effects on cPLA2alpha phosphorylation (44, 45), but the roles of the ERK and p38mapk pathways in controlling cytokine-stimulated prostanoid production are unknown. In the present study we establish that IL-1alpha acutely releases PGI2 from HUVEC and examine the involvement of cPLA2alpha and the p42/44mapk and p38mapk pathways in this early synthesis. Our results demonstrate the importance of early ERK-mediated activation of cPLA2alpha as a regulator of acute cytokine-stimulated PGI2 release and identify a novel, receptor-specific cross talk between the p38mapk and ERK pathways that may regulate the extent of prostanoid synthesis in agonist-stimulated human endothelial cells.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Materials. AA, human alpha -thrombin, bovine serum albumin (BSA; fraction V), pepstatin, aprotinin, leupeptin, sodium fluoride, sodium pyrophosphate, sodium orthovanadate, and sodium glycerophosphate were all purchased from Sigma (Poole, Dorset, UK). 4-(2-Aminoethyl)benzenesulfonyl fluoride (AEBSF), myelin basic protein, and protein G agarose were obtained from Calbiochem (Nottingham, UK). Human recombinant IL-1alpha was from R&D Systems (Oxford, UK). PD-98059, SB-203580, and U-0126 were generously provided by Dr. A. Saltiel (Parke Davis), Dr. J. Lee (Smith Kline Beecham), and Dr. J. M. Trzaskos (DuPont Merck), respectively. Anti-ACTIVE MAPK antibody recognizing the active, dually phosphorylated forms of p42/p44mapk, was from Promega (Southampton, UK); anti-p42/p44mapk antibody was from Affiniti Research Products (Nottingham, UK). Phosphospecific anti-p38mapk and anti-phospho-MEK1/2 antibodies were purchased from New England Biolabs (Beverly, MA). Anti-p38mapk antibody, protein A/G PLUS agarose, and glutathione-S-transferase (GST)-activating transcription factor (ATF)-21-96 were from Santa Cruz (Santa Cruz, CA). The polyclonal anti-cPLA2alpha antibody was a kind gift from Dr. R. Kramer (Eli Lilly, Indianapolis, IN). Horseradish peroxidase-conjugated goat anti-mouse/rabbit immunoglobulins were from Pierce and Warriner (Cheater, Cheshire, UK). Reagents for SDS-PAGE were from Bio-Rad (Hemel Hempstead, Hertfordshire, UK) and National Diagnostics (Hessle, Hull, UK). Polyvinylidene difluoride (PVDF) membranes (Immobilon-P) and I-Block were from Sigma and Tropix (Warrington, UK), respectively. Enhanced chemiluminescence (ECL) Western blotting detection reagents, Hyperfilm-ECL, and [5,6,8,9,11,12,14,15-3H]AA were all obtained from Amersham International (Amersham, UK). 125I-labeled 6-ketoprostaglandin F1alpha (6-keto-PGF1alpha ) was purchased from Metachem Diagnostics (Piddington, Northampton, UK). [gamma -32P]ATP and Renaissance 4CN Plus were from DuPont (Dreieich, Germany). Raf-1 immunoprecipitation kinase cascade assay kits were from Upstate Biotechnology (Lake Placid, NY). Culture media were purchased from Sigma or Life Technologies (Paisley, UK). All other reagents were obtained from Sigma or BDH (Poole, Dorset, UK) at the equivalent of analytical reagent grade.

Cell culture. HUVEC were isolated by collagenase digestion using a modification of a procedure originally described by Jaffe et al. (16). Primary HUVEC cultures were grown in medium 199 (M199) supplemented with 20% (vol/vol) fetal calf serum, L-glutamine (5 mM), NaHCO3 (25 mM), penicillin (50 U/ml), and streptomycin (50 U/ml) and maintained at 37°C in 5% CO2-95% air. All tissue culture plastic was precoated with gelatin (1%) before the cells were plated. On reaching confluence (~1 × 106 cells/25-mm2 flask), primary cultures were trypsinized by brief exposure to a trypsin/EDTA solution (0.1%/0.025% in phosphate-buffered saline; PBS), plated onto 75-mm2 flasks, and cultured in M199 additionally supplemented with heparin (90 µg/ml) and endothelial cell growth supplement (ECGS; 20 µg/ml). ECGS was prepared from porcine brain as described by Maciag et al. (23). When confluent (~3.5 × 106 cells/75-mm2 flask), cells were plated onto either 24-well tissue culture trays (~1 × 105 cells/well) or 60-mm-diameter tissue culture dishes (~1 × 106 cells/dish). Confluent passage 2 cells were subsequently used for experimentation 4-5 days after plating; all experiments were routinely conducted at 37°C.

Measurement of PGI2 release. Confluent cultures of HUVEC in 24-well tissue culture trays were washed with serum-free M199 supplemented with HEPES (25 mM) and glutamine (5 mM) (H-M199, pH 7.4). Cell monolayers were treated as described in legends to Figs. 1A and 4, and the PGI2 levels in the cell supernatants were quantified using a specific radioimmunoassay for 6-keto-PGF1alpha , the stable hydrolysis product of PGI2, as previously described (46). Supernatants from HUVEC monolayers used in immunoblotting studies were also routinely assayed for 6-keto-PGF1alpha content.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Interleukin-1alpha (IL-1alpha ) induces early arachidonic acid (AA) mobilization and prostacyclin (PGI2) release from cultured endothelial cells. A: confluent human umbilical vein endothelial cells (HUVEC) in 24-well tissue-culture trays were exposed to human recombinant IL-1alpha (; 100 U/ml) or vehicle control (open circle ) for the times indicated. Supernatants were sampled and assayed for 6-ketoprostaglandin F1alpha (6-keto-PGF1alpha ) as described in METHODS. B and C: confluent monolayers of HUVEC in 24-well tissue culture trays were prelabeled with [3H]AA for 24 h and subsequently incubated with varying concentrations of IL-1alpha for 30 min (B) or with vehicle (open circle ) or IL-1alpha (; 100 U/ml) for times ranging between 0 and 60 min (C). Radioactivity released into the supernatant was quantified as described in METHODS. Data are expressed as means ± SE of 3-4 observations per treatment from typical experiments taken from a series of 3-4 experiments for A-C (* P < 0.05, ** P < 0.01 vs. time-matched controls).

Measurement of [3H]AA release. Release of AA from endothelial cells was quantified as previously described (44). Briefly, confluent HUVEC monolayers in 24-well trays were incubated for 24 h with [5,6,8,9,11,12,14,15-3H]AA (1 µCi/ml) in serum-containing M199. After incubation, cells were washed twice in serum-free H-M199 and subsequently exposed to the same medium supplemented with 0.3% fatty acid-free BSA and other additions as indicated. At the end of the incubations the medium above the monolayers was collected and centrifuged for 5 min at 13,000 g, and the radioactivity in aliquots of supernatant was determined by beta-scintillation counting.

Immunoblotting procedures. Immunoblotting studies were performed essentially as previously described (45, 46). Briefly, confluent HUVEC in 60-mm-diameter dishes (~1 × 106 cells/dish) were serum deprived for 16 h in serum- and ECGS-free M199 supplemented with glutamine (5 mM). Those cultures that exhibited significant cell detachment on serum starvation were discarded. Monolayers were subsequently washed twice in H-M199 and challenged as detailed in legends to Figs. 2, 3, and 5-8. Incubations were terminated by washing with ice-cold PBS containing Na3VO4 (0.4 mM) and whole cell lysates prepared in lysis buffer [63.5 mM Tris · HCl (pH 6.8), 10% glycerol, 2% SDS, 1 mM Na3VO4, 1 mM AEBSF, 50 µg/ml leupeptin, 5% beta -mercaptoethanol, and 0.02% bromphenol blue]. The protein content of cell lysates was measured using a bicinchoninic acid (BCA) protein assay (Pierce and Warriner), and equal quantities of protein (100 µg/lane) were resolved by SDS-PAGE (10%). Gels were cast using a Protean II XI (20 cm) electrophoresis system (Bio-Rad). Samples were subjected to prolonged electrophoresis overnight and then transferred onto PVDF (Immobilon-P) membrane. Membranes were blocked for 3 h in TBST [50 mM Tris, 150 mM NaCl, and 0.02% (vol/vol) Tween 20, pH 7.4] containing 3% (wt/vol) BSA. For immunodetection of cPLA2alpha , blots were blocked for 2 h in 0.2% I-Block. Membranes were incubated overnight in TBST/0.2% BSA containing anti-p42/44mapk (1:25,000), anti-ACTIVE p42/p44 (1:20,000), anti-phospho-MEK1/2 (1:1,000), anti-cPLA2alpha (1:5,000), anti-p38mapk (1:1,000), or phosphospecific anti-p38mapk (1:500) antibody. Blots were then washed in TBST (8 × 15 min) and incubated with horseradish peroxidase-conjugated goat anti-rabbit/mouse IgG as appropriate (1:10,000) for 1 h. After further washing (8 × 15 min), immunoreactive bands were visualized either colorimetrically with Renaissance 4CN Plus or by enhanced chemiluminescence (ECL) according to the manufacturer's instructions. In experiments employing phosphospecific antisera, equal loading was verified by reprobing with antibody recognizing total protein. Enhanced phosphorylation/activation of either p42mapk or cPLA2alpha is reflected in a decreased electrophoretic mobility such that the active, phosphorylated forms of the enzymes are retarded in the gel. Where indicated, densitometric analysis of cPLA2alpha or p42mapk gel shifts was performed using a Bio-Rad Gel Doc 1000 system and Molecular Analyst software.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   IL-1alpha activates mitogen-activated protein kinase (MAPK) kinase (MEK) and p42mapk and enhances cytosolic phospholipase A2alpha (cPLA2alpha ) phosphorylation in a time-dependent manner. Confluent HUVEC in 60-mm-diameter tissue culture dishes were serum starved for 16 h. Washed monolayers were exposed to medium alone or to IL-1alpha (100 U/ml) for the times indicated, and whole cell lysates were prepared as described in METHODS. Cell lysates were subjected to SDS-PAGE followed by immunoblotting. Blots were probed with antisera recognizing either phosphorylated MEK1/2 (A), p42mapk (B), or cPLA2alpha (C). Immunoreactive proteins were visualized using enhanced chemiluminescence (ECL). Phosphorylated forms of the proteins are indicated (-P). The mobility shifts of phosphorylated vs. nonphosphorylated forms of p42mapk and cPLA2alpha are indicated. The positions of the molecular mass markers are given at left of each immunoblot. Immunoblots are from a representative experiment from a series of 4 with similar results.



View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   MEK inhibitors attenuate IL-1alpha -induced extracellular signal-regulated kinase (ERK) activation and cPLA2alpha phosphorylation. Quiescent HUVEC were pretreated for 30 min with vehicle alone or with the indicated concentrations of PD-98059 (A, top and B, top) or U-0126 (A, bottom and B, bottom) and subsequently exposed to buffer alone or to IL-1alpha (100 U/ml) for a further 30 min in the continued presence or absence of inhibitor. Immunoblots from whole cell lysates were probed with anti-p42mapk (A, top), anti-phospho-p42/44mapk (A, bottom), or anti-cPLA2alpha (B) antibodies, and immunoreactive proteins were visualized using ECL. Positions of phosphorylated and nonphosphorylated forms of p42/44mapk and cPLA2alpha are indicated. Blots are representative of results obtained in 4 separate experiments. C: densitometric analysis of the immunoblots shown in B. Open bars, nonphosphorylated cPLA2alpha ; hatched bars, phosphorylated cPLA2alpha ; solid bars, total (phosphorylated plus nonphosphorylated) cPLA2alpha .

Immunoprecipitation and immune-complex kinase assay of p38mapk. Confluent, quiescent HUVEC in 60-mm dishes were washed and treated as described for the immunoblotting studies. The medium was aspirated, and incubations were terminated by washing in ice-cold PBS supplemented with 0.4 mM Na3VO4; all subsequent procedures were carried out at 4°C. Monolayers were lysed in a buffer comprising 20 mM Tris · HCl, 137 mM NaCl, 2 mM EDTA, 25 mM beta -glycerolphosphate, 2 mM sodium pyrophosphate, 10% glycerol, 1% Triton X-100, 1 mM Na3VO4, 10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 40 µg/ml aprotinin (pH 7.4) and allowed to stand on ice for 30 min with gentle agitation. Whole cell lysates were centrifuged (4°C, 10 min, 13,000 g), and the supernatants were retrieved and transferred to fresh 1.5-ml microcentrifuge tubes. Equal amounts of lysate protein were subsequently incubated with anti-p38mapk antibody (10 µl/incubation) for 3 h at 4°C with constant rotation. Immune complexes were captured with protein A/G plus agarose (4°C, overnight). The bead suspensions were pelleted, and immunoprecipitates were washed twice in lysis buffer and twice in kinase buffer (25 mM HEPES, 25 mM beta -glycerolphosphate, 25 mM MgCl2, 2 mM dithiothreitol (DTT), 100 µM Na3VO4; pH 7.4). Immune-complex kinase activity was assayed by incubation for 30 min at 30°C in kinase buffer (25-µl final volume) containing [gamma -32P]ATP (5 µCi, 50 µM) and GST-ATF-2 (3 µg). Reactions were terminated by the addition of 2× concentrated Laemmli sample buffer. Proteins were resolved by SDS-PAGE (12%) and transferred to PVDF membrane, and GST-ATF-2 phosphorylation was assessed by autoradiography (-70°C).

Raf-1 immunoprecipitation and kinase activity assay. Quiescent HUVEC monolayers in 60-mm dishes were washed and treated as described in the legend to Table 1. Incubations were terminated by washing in ice-cold PBS supplemented with 0.4 mM Na3VO4; all subsequent procedures were carried out at 4°C. Raf-1 activity was assessed using a Raf-1 immunoprecipitation kinase cascade assay kit, according to the manufacturer's instructions. Briefly, 200 µl of buffer A [50 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 0.5 mM Na3VO4, 0.1% beta -mercaptoethanol, 1% Triton X-100, 50 mM NaF, 5 mM Na pyrophosphate, 10 mM Na glycerophosphate, 0.1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 1 µM okadaic acid] was applied to the monolayers, which were then placed on ice for 1 h. Whole cell lysates were collected and centrifuged (15 min, 16,000 g, 4°C). The resulting supernatants were precleared with protein G agarose and incubated (2 h with rotation; 4°C) with anti-Raf-1 antibody previously conjugated to protein G agarose. The bead suspensions were pelleted, and immunoprecipitates were washed twice in buffer A and once in assay dilution buffer (ADB: 20 mM MOPS, pH 7.2, 25 mM beta -glycerol phosphate, 5 mM EGTA, 1 mM Na3VO4, 1 mM DTT). The protein G agarose/enzyme immune complexes were subsequently incubated with inactive MEK1 and inactive ERK2 for 30 min at 30°C. Samples were then briefly centrifuged to pellet the beads, and 4 µl of the supernatant were removed and mixed with myelin basic protein (final concn 0.6 mg/ml) and [gamma -32P]ATP (10 µCi/tube), made up to a final volume of 34 µl with ADB. Samples were incubated for 10 min at 30°C and then slowly spotted onto P81 phosphocellulose squares. Membranes were washed in 0.75% phosphoric acid (3 × 5 min) and acetone (1 × 5 min) and transferred to scintillation vials containing 5 ml of scintillation cocktail, and radioactivity was quantified on a Beckman beta counter.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Effects of IL-1alpha , thrombin, and SB-203580 on Raf-1 activity

Statistical analysis. Data were analyzed for statistically significant differences between experimental conditions using ordinary ANOVA (Bonferroni multiple comparison test). Data are expressed as means ± SE; P < 0.05 was considered statistically significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

IL-1alpha stimulates arachidonate release and PGI2 synthesis in HUVEC monolayers. Exposure of confluent HUVEC monolayers to IL-1alpha at a maximally effective concentration (100 U/ml) resulted in significant accumulation of 6-keto-PGF1alpha after a 30-min incubation, which continued to increase for the duration of the experiment (Fig. 1A). In seven independent experiments the mean increase in PGI2 synthesis evoked by a 30-min exposure to IL-1alpha was 197 ± 27 (% over basal; ± SE). Parallel studies showed that neither COX-2 mRNA nor protein levels were enhanced in cells exposed to IL-1alpha for 30 min (data not shown); thus these early changes in prostanoid synthesis occurred in the absence of enhanced COX-2 expression. To examine the effects of IL-1alpha on AA mobilization, HUVEC monolayers were prelabeled with [3H]AA and exposed to IL-1alpha at various concentrations for different time periods. Consistent with PGI2 synthesis, early [3H]AA mobilization (30 min) in IL-1alpha -stimulated HUVEC was concentration dependent with maximal release achieved at 100 U/ml IL-1alpha (Fig. 1B) and occurred in a time-dependent manner (Fig. 1C). All subsequent experiments employed 100 U/ml IL-1alpha . TNF-alpha promoted similar early changes in AA release and PGI2 synthesis in HUVEC (data not shown). In accordance with our previous findings (44), thrombin at 1 U/ml elicited both a greater and more rapid release of AA compared with a maximal dose of IL-1alpha (15 min thrombin: 380 ± 48; 30 min thrombin 605 ± 82% increase over basal; mean ± SE from 3 independent experiments).

Effects of a cPLA2alpha inhibitor on AA release and PGI2 synthesis. Arachidonyl trifluoromethyl ketone (AACOCF3), a trimethyl ketone analog of AA, has been shown to inhibit cell-associated 85-kDa cPLA2alpha , as well as human recombinant 85-kDa cPLA2alpha (1, 27). To evaluate further the potential role of cPLA2alpha in cytokine-driven PGI2 generation, we examined the effects of AACOCF3 on [3H]AA release and PGI2 synthesis. Pretreatment (30 min) with AACOCF3 (10 µM) completely suppressed AA release in response to a 30-min exposure to IL-1alpha (IL-1, 118 ± 4%; IL-1 plus AACOCF3, 103 ± 5% increase over basal; mean ± SE, n = 3). AA release under basal conditions was also partially, but not significantly, inhibited after AACOCF3 treatment. In parallel experiments AACOCF3 (10 µM) also attenuated IL-1alpha -stimulated PGI2 formation (IL-1, 182 ± 24%; IL-1 plus AACOCF3, 100 ± 13% increase over basal; mean ± SE, n = 3) without significantly modifying basal PGI2 synthesis (AACOCF3 alone, 105 ± 20%). These results demonstrate that IL-1alpha promotes early AA release in a cPLA2alpha -dependent manner.

Phosphorylation of MEK, p42mapk, and cPLA2alpha in HUVEC exposed to IL-1alpha . We have previously reported that inhibition of MEK, the upstream activator of p42mapk, attenuates thrombin- or VEGF-induced PGI2 release and that this results from inhibition of p42mapk-mediated cPLA2alpha phosphorylation (44, 45). To determine whether these mechanisms contribute to the acute release of PGI2 from IL-1alpha -stimulated HUVEC, we examined the effects of IL-1alpha on activation of MEK and p42mapk and on the phosphorylation state of cPLA2alpha . Phosphorylated MEK was detected in whole cell HUVEC lysates under basal conditions and increased in a time-dependent manner in response to IL-1alpha with maximal phosphorylation observed after 20-30 min (Fig. 2A). Consistent with this time course, and confirming our recent observations (28, 45), IL-1alpha promoted a pronounced, time-dependent increase in the upper, electrophoretically slower band of p42mapk and a concomitant decrease in the lower band (Fig. 2B). Increased phosphorylation was detected by 15-20 min, reached a maximum at 30 min, and decreased after 60 min of incubation with IL-1alpha . As previously described (44), phosphorylated and nonphosphorylated forms of cPLA2alpha are present in nonstimulated HUVEC (Fig. 2C). Enhancement of cPLA2alpha phosphorylation by IL-1alpha followed kinetics similar to those for p42mapk, with maximally elevated phospho-cPLA2alpha evident at 20-30 min (Fig. 2C); in contrast, cPLA2alpha phosphorylation was maintained for up to 2 h after IL-1alpha stimulation (Fig. 2C and data not shown). Thus enhanced activation of MEK, p42mapk, and cPLA2alpha coincides temporally with the onset of AA mobilization and PGI2 synthesis in IL-1alpha -stimulated HUVEC.

Inhibition of MEK modulates IL-1alpha -induced p42mapk activation, cPLA2alpha phosphorylation, and PGI2 synthesis. The close correlation between IL-1alpha -induced p42mapk/cPLA2alpha phosphorylation and PGI2 generation prompted us to investigate further the potential role of the MEK/ERK/cPLA2alpha pathway in acute, cytokine-driven PGI2 formation. Prior treatment of HUVEC (30 min) with the cell-permeant MEK inhibitors PD-98059 (9) or U-0126 (10) dose-dependently attenuated IL-1alpha -induced ERK activation, with complete inhibition observed at 5 or 1 µM, respectively (Fig. 3A). Treatment with IL-1alpha caused a nearly complete gel shift of cPLA2alpha that was partially inhibited by PD-98059 concentrations of 5 µM and above and by 0.1-3 µM U-0126 (Fig. 3B). These findings were confirmed by densitometric analysis of the immunoblots, with a maximal inhibition of ~50% with either inhibitor (Fig. 3C). In accordance with this partial inhibitory effect, IL-1alpha -stimulated [3H]AA release was inhibited by 12 ± 2% (mean ± SE; n = 3 independent experiments) after treatment with 5 µM PD-98059. PD-98059 also caused a dose-dependent reduction of basal and IL-1alpha -induced PGI2 release (Fig. 4A). Interestingly, PGI2 synthesis was totally blocked at 1 µM PD-98059, a concentration that partially inhibited IL-1alpha -stimulated p42mapk activation (Fig. 3A) and did not detectably reduce cPLA2alpha phosphorylation (Fig. 3B). In contrast, U-0126, at a concentration (1 µM) that abolished IL-1alpha -stimulated ERK activation and maximally affected cPLA2alpha phosphorylation (Fig. 3), reduced IL-1alpha -evoked PGI2 synthesis by only 59 ± 5% (mean ± SE, n = 3 independent experiments). These results show that ERK-dependent and -independent mechanisms regulated cPLA2alpha phosphorylation in response to IL-1alpha and that inhibition of cPLA2alpha activation correlates with PGI2 synthesis.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of PGI2 synthesis by PD-98059 and SB-203580. HUVEC in 24-well trays were incubated for 30 min with the indicated concentrations of PD-98059 (A) or SB-203580 (B) followed by treatment with vehicle alone (open bars) or with 100 U/ml IL-1alpha (hatched bars) for a further 30 min in the continued absence or presence of inhibitor. 6-keto-PGF1alpha formation was quantified by radioimmunoassay as described in METHODS. Data are means ± SE of 3 observations from single experiments representative of 4 with each inhibitor (* P < 0.05, ** P < 0.01, *** P < 0.001).

Activation of p38mapk by IL-1alpha and thrombin. To address the potential role of p38mapk in cytokine-driven prostanoid synthesis, we initially measured p38mapk activation by immune-complex kinase assay. Treatment with IL-1alpha or thrombin enhanced p38mapk activity, which was partially attenuated by the p38mapk inhibitor SB-203580 (Fig. 5C). The incomplete inhibition of p38mapk reflects the rapid reversibility of SB-203580:p38mapk interaction during immunoprecipitation (43). SB-203580 also dose-dependently suppressed agonist-stimulated p38mapk activation when added directly to immunoprecipitates (data not shown). IL-1alpha and thrombin enhanced phosphorylation of p38mapk (Fig. 5, A and B), and this was unaffected by SB-203580 treatment (data not shown). The kinetics of the responses differed, with transient or sustained activation observed in response to IL-1alpha or thrombin, respectively. In addition, IL-1alpha -stimulated p38mapk activation (5 min) occurred more rapidly than p42mapk phosphorylation (20-30 min; Fig. 2), whereas p42mapk activation by thrombin (1 min; Refs. 44 and 45) was earlier than p38mapk activation (Fig. 5B). Neither PD-98059 nor U-0126 affected the phosphorylation state or activity of p38mapk as assessed by in-gel kinase assay (data not shown). Thus both IL-1alpha and thrombin activate p38mapk but with different kinetics.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of IL-1alpha and thrombin on p38mapk phosphorylation and activity. A and B: quiescent HUVEC were exposed to medium alone [control (C)], to IL-1alpha (100 U/ml; A) or to thrombin (1 U/ml; B) for the times indicated. Whole cell lysates were subjected to SDS-PAGE followed by immunoblotting with a phosphospecific p38mapk antibody. Immunoreactive proteins were visualized using ECL. The position of phosphorylated p38mapk (p38-P) is indicated. C: quiescent HUVEC were pretreated for 30 min with SB-203580 (30 µM) and then challenged with vehicle (C), thrombin (T; 1 U/ml, 15 min), or IL-1alpha (IL; 100 U/ml, 30 min). p38mapk was immunoprecipitated from whole cell lysates, and its activity was measured by assessing the phosphorylation of GST-ATF-2 as described in METHODS. Blots in A-C are each representative of 2 separate experiments with similar results.

Effects of SB-203580 on agonist-stimulated PGI2 synthesis, p42mapk activation, and cPLA2alpha phosphorylation. In contrast to the inhibitory effects of MEK inhibition on IL-1alpha -induced p42mapk activation and cPLA2alpha phosphorylation, blockade of p38mapk enhanced the phosphorylation of p42mapk (>= 1 µM SB-203580; Fig. 6B) and cPLA2alpha (Fig. 6C). Consistent with these effects SB-203580 strongly potentiated IL-1alpha -stimulated MEK phosphorylation (Fig. 6A). However, despite potentiation of the MEK/ERK/cPLA2alpha pathway, SB-203580 markedly inhibited basal and IL-1alpha (100 U/ml)-stimulated PGI2 release (Fig. 4B). In contrast to our findings in IL-1-stimulated HUVEC, SB-203580 dose-dependently reduced activation of MEK, p42mapk, and cPLA2alpha in response to thrombin (Fig. 7).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 6.   SB-203580 potentiates IL-1alpha -stimulated MEK phosphorylation, p42/44mapk activation, and cPLA2alpha phosphorylation. Quiescent HUVEC were pretreated for 30 min with vehicle or with the indicated concentrations of SB-203580 and then challenged with either medium alone or IL-1alpha (100 U/ml) for a further 30 min in the continued presence of inhibitor. Cell lysates were analyzed by immunoblotting with either anti-phospho-MEK1/2 (A), anti-phospho-p42/44mapk (B), or anti-cPLA2alpha (C) antibodies. Immunoreactive proteins were visualized using ECL. Positions of the phosphorylated forms are indicated (-P). Immunoblots are each representative of results obtained from 2-3 separate experiments.



View larger version (46K):
[in this window]
[in a new window]
 
Fig. 7.   Inhibition of thrombin-stimulated MEK, p42/44mapk, and cPLA2alpha phosphorylation by SB-203580. Quiescent HUVEC monolayers were pretreated for 30 min with vehicle or with the indicated concentrations of SB-203580 and subsequently exposed to vehicle or thrombin (1 U/ml) for a further 10 min in the continued presence of inhibitor. Whole cell lysates were separated by SDS-PAGE and analyzed by immunoblotting with anti-phospho-MEK1/2 (A), anti-phospho-p42/44mapk (B), or anti-cPLA2alpha (C) antibodies. Immunoreactive proteins were visualized using ECL. Positions of the phosphorylated forms are indicated (-P). Immunoblots are each representative of results obtained from 2-3 separate experiments.

Effects of IL-1alpha and thrombin on Raf-1 activation. To determine whether the differential effects of SB-203580 on IL-1alpha - vs. thrombin-mediated ERK activation reflect differences in the signaling components upstream of ERK, we measured Raf-1 activation in immunoprecipitates from thrombin- and IL-1-stimulated cells (Table 1). At the time points examined, IL-1alpha , but not thrombin, significantly elevated Raf-1 activity, suggesting that thrombin uses alternative pathway(s) to activate MEK. Because Raf-1 activity was enhanced in the presence of SB-203580 alone, SB-203580 treatment resulted in strong potentiation of Raf-1 activity in both IL-1alpha - and thrombin-stimulated HUVEC. Thus the opposing effects of p38mapk blockade on IL-1alpha - (Fig. 6) vs. thrombin-induced p42/44mapk activation (Fig. 7) cannot be explained by differential effects of the inhibitor on Raf-1 activation.

MEK inhibitors block COX activity in HUVEC. To examine whether inhibition of IL-1alpha -stimulated PGI2 release by SB-203580 (despite enhancement of MEK/ERK/cPLA2alpha phosphorylation) reflects an independent action of the p38mapk inhibitor on COX activity, we measured PGI2 synthesis after application of exogenous AA (Table 2). SB-203580 attenuated AA-induced PGI2 formation. Parallel studies showed that PD-98059 also inhibited AA-stimulated PGI2 synthesis, whereas U-0126 (1 µM) had no significant effect (Table 2), confirming that SB-203580 and PD-98059 block COX activity at concentrations that maximally effect ERK/p38mapk activation, whereas U-0126 does not. Because indomethacin did not modulate IL-1alpha -induced p42/44mapk activation or cPLA2alpha phosphorylation (Fig. 8), the effects of the MEK/p38mapk inhibitors on IL-1alpha -stimulated ERK/cPLA2alpha phosphorylation did not result from their ability to block COX activity.

                              
View this table:
[in this window]
[in a new window]
 
Table 2.   Effects of MEK inhibitors, SB-203580, and indomethacin on 6-keto-PGF1alpha formation



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 8.   Indomethacin does not modulate IL-1alpha -stimulated p42/44mapk activation or cPLA2alpha phosphorylation. Quiescent HUVEC monolayers in 60-mm-diameter tissue-culture trays were treated for 30 min with vehicle or with the indicated concentrations of indomethacin. Cells were subsequently challenged with IL-1alpha for 30 min, and the resulting cell lysates were analyzed by immunoblotting with antisera recognizing the active, dually phosphorylated forms of p42mapk and p44mapk (A) or cPLA2alpha (B). The phosphorylated forms of p42/p44mapk and cPLA2alpha are indicated (-P). Results are from a single experiment representative of 3 with similar results.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The cytosolic, AA-selective 85-kDa cPLA2alpha is important in mediating agonist-driven AA mobilization in several cell types (21). This release initiates the biosynthesis of PGs, leukotrienes, and platelet-activating factor, all of which are implicated in the modulation of diverse physiological and pathophysiological processes, including vascular homeostasis and inflammation. The proinflammatory cytokines IL-1 and TNF-alpha have been shown to promote PGI2 generation by ECs, but their effects are generally delayed in onset and require de novo protein synthesis (5, 15). In the present study we have focused on the post-receptor transduction pathways regulating early changes in cytokine-driven prostanoid synthesis and have demonstrated that IL-1alpha stimulates acute PGI2 synthesis in part via a MEK/p42mapk/cPLA2alpha pathway. Thus 1) MEK, p42mapk, and cPLA2alpha were phosphorylated by IL-1alpha with kinetics coinciding with the onset of AA mobilization and PGI2 synthesis, 2) AACOCF3, at concentrations previously reported to modify stimulus-induced AA generation, markedly suppressed IL-1alpha -driven AA release and PGI2 synthesis, consistent with a key role for the 85-kDa cPLA2alpha , and 3) inhibition of MEK attenuated cytokine-stimulated p42mapk activation, cPLA2alpha phosphorylation, and PGI2 formation. We (44, 45) and others (7) have previously shown that rapid PGI2 synthesis in response to Ca2+-mobilizing agonists that promote cPLA2alpha translocation also requires p42mapk-mediated cPLA2alpha phosphorylation, and several studies have suggested that phosphorylated cPLA2alpha fails to mobilize AA in the absence of an increase in intracellular Ca2+ concentration ([Ca2+]i) (e.g., Ref. 48). Because acute exposure to IL-1alpha neither raises [Ca2+]i nor causes translocation of cPLA2alpha (Ref. 11; Houliston and Wheeler-Jones, unpublished observations), these studies provide evidence that enhanced cPLA2alpha phosphorylation alone may be sufficient to promote AA mobilization in IL-1alpha -stimulated HUVEC. It is possible that cPLA2alpha activation by IL-1alpha may result from phosphorylation of discrete pools of the enzyme that are already localized within the membrane at resting [Ca2+]i (34). Although there are likely to be several alternative cell-specific mechanisms for cPLA2alpha regulation (12, 30, 32, 38, 47), our findings are in keeping with recent studies suggesting that cPLA2alpha phosphorylation becomes most important for activation when the rise in [Ca2+]i is insufficient to fully translocate the enzyme (14). The contribution, if any, of the novel, Ca2+-independent cPLA2beta and -gamma isoforms to IL-1alpha -stimulated AA release in HUVEC remains to be defined (35, 40, 42).

Our findings implicating ERK activation in IL-1alpha -induced AA/PGI2 release are based on pharmacological inhibition with PD-98059 or U-0126, two structurally and mechanistically distinct inhibitors of MEK. Under conditions where p42/44mapk activation by IL-1alpha was abolished, IL-1alpha -evoked cPLA2alpha phosphorylation was only partially inhibited by either of these agents, indicating that MEK-dependent and MEK-independent pathway(s) both regulate early changes in cPLA2alpha phosphorylation in response to cytokine. The partial reductions in IL-1alpha -stimulated AA mobilization and PGI2 synthesis after MEK inhibition are also consistent with the effects on cPLA2alpha phosphorylation.

In contrast to our present findings in human ECs, p42/p44mapk does not mediate phosphorylation of cPLA2alpha in thrombin- or collagen-stimulated platelets (3), and current evidence suggests that p38mapk plays a central role in these cells (2, 14, 43). Our results suggest that p38mapk activation is unlikely to account for the MEK-independent phosphorylation since SB-203580, a pyridinyl imidazole inhibitor of p38mapk activity (49), did not inhibit IL-1alpha -induced cPLA2alpha phosphorylation in HUVEC. It is possible that p38mapk directly or indirectly (14) phosphorylates cPLA2alpha on Ser727, which does not alter the mobility of cPLA2alpha on SDS-PAGE (36), or alternatively, that an SB-203580-insensitive p38mapk isoform contributes to Ser505 phosphorylation in IL-1alpha -stimulated endothelium (19).

Our results demonstrated that SB-203580 and PD-98059, but not U-0126, reduced PGI2 generation in response to exogenous AA, suggesting additional inhibitory effects on COX (4, 18). Inhibition of COX activity at low concentrations may explain why PD-98059 had a more potent effect on PGI2 synthesis compared with its effects on p42mapk/cPLA2alpha activation. However, inhibition of COX activity with indomethacin did not mimic the effects of either SB-203580 or PD-98059 on cytokine- or thrombin-stimulated p42mapk/cPLA2alpha activation, suggesting that the effects of these inhibitors did not result from COX inhibition and are mediated by blockade of p38mapk and ERK, respectively. More importantly, U-0126, an inhibitor of MEK with no capacity to block COX in HUVEC, mimicked the partial inhibitory effects of PD-98059 on ERK/cPLA2alpha phosphorylation and also partially inhibited PGI2 synthesis. These results confirm that PGI2 generation is regulated in part via a MEK/ERK/cPLA2alpha -dependent pathway.

The present studies also confirmed that SB-203580 treatment inhibited agonist-stimulated p38mapk activity. As discussed above, blocking p38mapk activity had no inhibitory effect on IL-1alpha -stimulated cPLA2alpha phosphorylation but, in contrast, potentiated cytokine-driven cPLA2alpha phosphorylation and p42mapk activation. These results imply that early triggering of the p38mapk pathway by IL-1alpha limits the extent of subsequent activation of p42/p44mapk and thus of the downstream events regulated by these kinases. The earlier (5 min) activation of p38mapk in cytokine-stimulated HUVEC compared with that of p42/44mapk (20-30 min; Ref. 28) is also consistent with this hypothesis. The modulatory effects of p38mapk on p42/44mapk activation are unlikely to reflect direct association of p38 with ERK (51) because 1) MEK activation in SB-203580-treated cells is modulated in parallel with ERK, and 2) immunoprecipitation of p38mapk does not coprecipitate p42/p44mapk (Houliston and Wheeler-Jones, unpublished observations); communication between the p38 and p42/p44mapk pathways is therefore likely to occur at the level of upstream regulatory kinases. Furthermore, because IL-1alpha -induced p38mapk activation was not affected by inhibiting the MEK/ERK pathway, the interaction between ERK and p38mapk pathways occurs in a unidirectional manner. In marked contrast to IL-1alpha , blocking p38mapk activation had a differential effect on thrombin-mediated signaling, causing inhibition of MEK, p42/44mapk, and cPLA2alpha phosphorylation. These data suggest that p38mapk activation positively regulates the ERK pathway in thrombin-stimulated cells and may therefore contribute to both the early (45) and sustained phases of p42/44mapk activation observed in response to thrombin (Houliston and Wheeler-Jones, unpublished observations). Because MEK1/2 and p42/44mapk were modified in parallel by SB-203580 treatment, it is likely that the level of regulation by p38mapk is proximal to MEK1/2 activation. However, measurement of Raf-1 activation by immune-complex kinase assay showed that SB-203580 in the absence of agonist strongly activated Raf-1 (17). In addition, IL-1alpha but not thrombin elevated Raf-1 activity in HUVEC, demonstrating that alternative Raf-1-independent pathways leading to MEK activation are recruited in thrombin-stimulated cells. The ability of SB-203580 alone to activate Raf-1 caused potentiation of activity in cells subsequently exposed to either IL-1alpha or thrombin, suggesting that the different effects of SB-203580 on signaling by these two agonists cannot be explained by effects at the level of Raf-1. Different types of cross talk between MAPK pathways are emerging, and the functional outcomes of such interactions are likely to be cell-type specific (20, 22, 29, 50). Our results suggest that differences in the onset and duration of p38mapk vs. p42/44mapk activation may determine how these pathways are coordinated to produce the physiological prostanoid responses of IL-1alpha - or thrombin-challenged ECs. A putative signaling pathway that could account for our observations is shown in Fig. 9.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 9.   Regulation of AA release and PGI2 synthesis by MAPK pathways in thrombin- vs. IL-1-stimulated HUVEC. MEKK, MEK kinase; MEKKK; MEK kinase kinase; SB, SB-203580.

In summary, we have shown that IL-1alpha stimulates early cPLA2alpha phosphorylation, AA mobilization, and PGI2 synthesis in HUVEC through activation of MEK-dependent and -independent pathways. SB-203580-sensitive p38mapk(s) negatively regulate ERK signaling after IL-1alpha treatment but facilitate thrombin signaling via the MEK/ERK pathway. These effects may reflect differential usage by IL-1alpha and thrombin of signaling elements upstream of p42/44mapk activation. These findings underscore the importance of MAPK cascades in regulating acute events in human endothelium.


    ACKNOWLEDGEMENTS

We thank Dr. A. Saltiel, Dr. J. Lee, Dr. J. M. Trzaskos, and Dr. R. Kramer for gifts of PD-98059, SB-203580, U-0126, and anti-cPLA2alpha antibody, respectively. We also thank the midwives and delivery staff at St. Mary's and the Portland Hospitals, London, UK, for assistance in obtaining umbilical cords.


    FOOTNOTES

This work was supported by the British Heart Foundation.

Address for reprint requests and other correspondence: C. P. D. Wheeler-Jones, Dept. of Veterinary Basic Sciences, The Royal Veterinary College, Univ. of London, Royal College St., London NW1 0TU, UK (E-mail: cwheeler{at}rvc.ac.uk).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 22 February 2001; accepted in final form 12 June 2001.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Bartoli, F, Lin HK, Ghomashchi F, Gelb MH, Jain MK, and Apitz-Castro R. Tight binding inhibitors of 85-kDa phospholipase A2 but not 14-kDa phospholipase A2 inhibit release of free arachidonic acid in thrombin-stimulated human platelets. J Biol Chem 269: 15625-15630, 1994[Abstract/Free Full Text].

2.   Borsch-Haubold, AG, Bartoli F, Asselin J, Dudler T, Kramer RM, Apitz-Castro R, Watson SP, and Gelb MH. Identification of the phosphorylation sites of cytosolic phospholipase A2 in agonist-stimulated human platelets and HeLa cells. J Biol Chem 273: 4449-4458, 1998[Abstract/Free Full Text].

3.   Borsch-Haubold, AG, Kramer RM, and Watson SP. Cytosolic phospholipase A2 is phosphorylated in collagen- and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase. J Biol Chem 270: 25885-25892, 1995[Abstract/Free Full Text].

4.   Borsch-Haubold, AG, Pasquet S, and Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by kinase inhibitors SB203580 and PD98059. SB203580 also inhibits thromboxane synthase. J Biol Chem 44: 28766-28772, 1998.

5.   Breviario, F, Prosperio P, Bertocchi F, Lampugnami MG, Mantovani A, and Dejana E. Interleukin-1 stimulates prostacyclin production by cultured human endothelial cells by increasing arachidonic acid mobilisation and conversion. Arteriosclerosis 10: 129-134, 1990[Abstract].

6.   Camacho, M, Lopez-Belmonte J, and Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ Res 83: 353-365, 1998[Abstract/Free Full Text].

7.   Carter, TD, Hallam TJ, Cusack NJ, and Pearson JD. Regulation of P(2y)-purinoceptor-mediated prostacyclin release from human endothelial cells by cytoplasmic calcium concentration. Br J Pharmacol 95: 1181-1190, 1988[Abstract].

8.   Carter, TD, and Pearson JD. Regulation of prostacyclin synthesis in endothelial cells. News Physiol Sci 7: 64-69, 1992[Abstract/Free Full Text].

9.   Dudley, DT, Pang L, Decker SJ, Bridges AJ, and Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7686-7689, 1995[Abstract].

10.   Favata, MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, and Trzaskos JM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998[Abstract/Free Full Text].

11.   Garcia, JGN, Stasek JE, Bahler C, and Natarajan V. Interleukin 1-stimulated prostacyclin synthesis in endothelium---lack of phospholipase-C, phospholipase-D, or protein-kinase-C involvement in early signal transduction. J Lab Clin Med 120: 929-940, 1992[ISI][Medline].

12.   Gijon, MA, Spencer DM, Siddiqi AR, Bonventre JV, and Leslie CC. Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that do and do not mobilise calcium. J Biol Chem 275: 20146-20156, 2000[Abstract/Free Full Text].

13.   Gorden, RD, Leighton IA, Campbell DG, Cohen P, Creaney A, Wilton DC, Masters DJ, Ritchie GA, Mott R, Taylor IW, Bundell KR, Douglas L, Morton J, and Needham M. Cloning and expression of cytosolic phospholipase A2 (cPLA2) and a naturally occurring variant. Phosphorylation of Ser505 of recombinant cPLA2 by p42 mitogen-activated protein kinase results in an increase in specific activity. Eur J Biochem 238: 690-697, 1996[Abstract].

14.   Hefner, Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D, Ghomashchi F, Yates JR, III, Armstrong CG, Paterson A, Cohen P, Fukunaga R, Hunter T, Kudo I, Watson SP, and Gelb MH. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinase. J Biol Chem 275: 37542-37551, 2000[Abstract/Free Full Text].

15.   Hla, T, and Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89: 7384-7388, 1992[Abstract].

16.   Jaffe, EA, Nachman RL, Becker CG, and Minick RC. Culture of human umbilical endothelial cells derived from umbilical veins. J Clin Invest 52: 2745-2756, 1973[ISI][Medline].

17.   Kalmes, A, Deou J, Clowes AW, and Daum G. Raf-1 is activated by p38 mitogen-activated protein kinase inhibitor, SB203580. FEBS Lett 444: 71-74, 1999[ISI][Medline].

18.   Kramer, RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ, and Jakubowski JA. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilisation of arachidonic acid by cPLA2. J Biol Chem 271: 27723-27729, 1996[Abstract/Free Full Text].

19.   Kumar, S, McDonnell PC, Gum RJ, Hand AT, Lee JC, and Young PR. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 235: 533-538, 1997[ISI][Medline].

20.   Kusuhara, M, Takahashi E, Peterson TE, Abe JI, Ishida M, Han J, Ulevitch RJ, and Berk BC. p38 kinase is a negative regulator of angiotensin II signal transduction in vascular smooth muscle cells. Effects on Na+/H+ exchange and ERK1/2. Circ Res 83: 824-831, 1998[Abstract/Free Full Text].

21.   Leslie, CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 272: 16709-16712, 1997[Free Full Text].

22.   Ludwig, S, Hoffmeyer A, Goebeler M, Kilian K, Hafner H, Neufeld B, Han J, and Rapp UR. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-related kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J Biol Chem 273: 1917-1922, 1998[Abstract/Free Full Text].

23.   Maciag, T, Cerundolo J, Ilsley S, Kelley PR, and Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA 76: 5674-5678, 1979[Abstract].

24.   Maier, JAM, Hla T, and Macaig T. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 265: 10805-10808, 1990[Abstract/Free Full Text].

25.   Malarkey, K, Belham CM, Paul A, Graham A, McLees A, Scott PH, and Plevin R. The regulation of tyrosine kinase signalling pathways by growth factor and G-protein-coupled receptors. Biochem J 309: 361-375, 1995[ISI][Medline].

26.   Marcus, AJ, Weksler BB, and Jaffe EA. Enzymatic conversion of prostaglandin endoperoxide H2 and arachidonic acid to prostacyclin by cultured human endothelial cells. J Biol Chem 253: 7138-7141, 1978[ISI][Medline].

27.   Marshall, LA, Bolognase B, Winkler JD, and Roshak A. Depletion of human monocyte 85-kDa phospholipase A2 does not alter leukotriene formation. J Biol Chem 272: 759-765, 1997[Abstract/Free Full Text].

28.   May, MJ, Wheeler-Jones CPD, Houliston RA, and Pearson JD. Activation of p42mapk in human umbilical vein endothelial cells by interleukin-1alpha and tumor necrosis factor-alpha . Am J Physiol Cell Physiol 274: C789-C798, 1998[Abstract/Free Full Text].

29.   Morooka, T, and Nishida E. Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells. J Biol Chem 273: 24285-24288, 1998[Abstract/Free Full Text].

30.   Mosior, M, Six DA, and Dennis EA. Group IV cytosolic phospholipase A2 binds with high affinity and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dramatic increases in activity. J Biol Chem 273: 2184-2191, 1998[Abstract/Free Full Text].

31.   Murakami, M, Kudo I, and Inoue K. Molecular nature of phospholipases A2 involved in prostaglandin I2 synthesis in human umbilical vein endothelial cells. Possible interaction of cytosolic and extracellular type II phospholipases A2. J Biol Chem 268: 839-844, 1993[Abstract/Free Full Text].

32.   Nakatani, Y, Tanioka T, Sunaga S, Murakami M, and Kudo I. Identification of a cellular protein that functionally interacts with the C2 domain of cytosolic phospholipase A2alpha . J Biol Chem 275: 1161-1168, 2000[Abstract/Free Full Text].

33.   Nemenoff, RA, Winitz S, Qian NX, Van Putten V, Johnson GL, and Heasley LE. Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C. J Biol Chem 268: 1960-1964, 1993[Abstract/Free Full Text].

34.   Osterhout, JL, and Shuttleworth TJ. A Ca2+-independent activation of a type IV cytosolic phospholipase A2 underlies the receptor stimulation of arachidonic acid-dependent noncapacitative calcium entry. J Biol Chem 275: 8248-8254, 2000[Abstract/Free Full Text].

35.   Pickard, RT, Strifler BA, Kramer RM, and Sharp JD. Molecular cloning of the two new human paralogs of 85-kDa cytosolic phospholipase A2. J Biol Chem 274: 8823-8831, 1999[Abstract/Free Full Text].

36.   Qui, ZH, Gijon MA, de Carvalho MS, Spencer DM, and Leslie CC. The role of calcium and phosphorylation of cytosolic phospholipase A2 in regulating arachidonic acid release in macrophages. J Biol Chem 273: 8203-8211, 1998[Abstract/Free Full Text].

37.   Raingeaud, J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, and Davis RJ. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270: 7420-7426, 1995[Abstract/Free Full Text].

38.   Read, MA, Whitley MZ, Gupta S, Pierce JW, Best J, Davis RJ, and Collins T. Tumour necrosis factor alpha  induced E-selectin expression is activated by the nuclear factor-kappa B and c-jun N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 272: 2753-2761, 1997[Abstract/Free Full Text].

39.   Schievella, AR, Regier MK, Smith WL, and Lin LL. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem 270: 30749-30754, 1995[Abstract/Free Full Text].

40.   Song, C, Chang XJ, Bean KM, Proia MS, Knopf JL, and Kriz RW. Molecular characterisation of cytosolic phospholipase A2-beta . J Biol Chem 274: 17063-17067, 1999[Abstract/Free Full Text].

41.   Su, B, and Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402-411, 1996[ISI][Medline].

42.   Underwood, KW, Song C, Kriz RW, Chang XJ, Knopf JL, and Lin LL. A novel calcium-independent phospholipase A2, cPLA2-gamma , that is prenylated and contains homology to cPLA2. J Biol Chem 273: 21926-21932, 1998[Abstract/Free Full Text].

43.   Waterman, WH, Molski TFP, Huang CK, Adams JL, and Sha'afi RI. Tumor necrosis factor-alpha -induced phosphorylation and activation of cytosolic phospholipase A2 are abrogated by an inhibitor of the p38 mitogen-activated protein kinase cascade in human neutrophils. Biochem J 319: 17-20, 1996[ISI][Medline].

44.   Wheeler-Jones, CPD, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, and Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 420: 28-32, 1997[ISI][Medline].

45.   Wheeler-Jones, CPD, May MJ, Houliston RA, and Pearson JD. Inhibition of MAP kinase kinase (MEK) blocks endothelial PGI2 release but has no effect on von Willebrand factor secretion or E-selectin expression. FEBS Lett 388: 180-184, 1996[ISI][Medline].

46.   Wheeler-Jones, CPD, May MJ, Morgan AJ, and Pearson JD. Protein tyrosine kinases regulate agonist-stimulated prostacyclin release but not von Willebrand factor secretion from human umbilical vein endothelial cells. Biochem J 315: 407-416, 1996[ISI][Medline].

47.   Wu, T, Angus CW, Yao XL, Logun C, and Shelhamer JH. p11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDa cytosolic phospholipase A2. J Biol Chem 272: 17145-17153, 1997[Abstract/Free Full Text].

48.   Xu, XX, Rock CO, Qui ZH, Leslie CC, and Jackowski S. Regulation of cytosolic phospholipase A2 phosphorylation and eicosanoid production by colony-stimulating factor 1. J Biol Chem 269: 31693-31700, 1994[Abstract/Free Full Text].

49.   Young, PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, and Lee JC. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272: 12116-12121, 1997[Abstract/Free Full Text].

50.   Zhang, C, Baumgartner RA, Yamada K, and Beaven MA. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases. J Biol Chem 272: 13397-13402, 1997[Abstract/Free Full Text].

51.   Zhang, H, Shi X, Hampong M, Blanis L, and Pelech S. Stress induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J Biol Chem 276: 6905-6908, 2001[Abstract/Free Full Text].


Am J Physiol Cell Physiol 281(4):C1266-C1276
0363-6143/01 $5.00 Copyright © 2001 the American Physiological Society